Comparison of immune persistence among inactivated and live attenuated hepatitis a vaccines 2 years after a single dose. Issue 9 (1st September 2016)
- Record Type:
- Journal Article
- Title:
- Comparison of immune persistence among inactivated and live attenuated hepatitis a vaccines 2 years after a single dose. Issue 9 (1st September 2016)
- Main Title:
- Comparison of immune persistence among inactivated and live attenuated hepatitis a vaccines 2 years after a single dose
- Authors:
- Zhang, Xiaoshu
An, Jing
Tu, Aixia
Liang, Xuefeng
Cui, Fuqiang
Zheng, Hui
Tang, Yu
Liu, Jianfeng
Wang, Xuxia
Zhang, Ningjing
Li, Hui - Abstract:
- ABSTRACT: Objective : Compare immune persistence from one dose of each of 3 different hepatitis A vaccines when given to school-age children: a domestic, live attenuated hepatitis A vaccine (H2 vaccine); a domestic inactivated hepatitis A vaccine (Healive®); and an imported, inactivated hepatitis A vaccine (Havrix®), .Methods : School-age children were randomized into 1 of 4 groups to receive a single dose of a vaccine: H2 vaccine, Healive®, Havrix®, or hepatitis B vaccine [control]. Serum samples were collected 12 and 24 months after vaccination for measurement of anti-HAV IgG using microparticle enzyme immunoassay. Seropositivity was defined as ≥ 20 mUI/ml. We compared groups on seropositivity and geometric mean concentration (GMC).Results : Seropositive rates for the H2, Healive®, Havrix®, and control groups were 64%, 94.4%, 73%, and 1.0%, respectively, 12-months post-vaccination; and 63%, 95.6%, 72%, and 1.0%, respectively 24-months post-vaccination. Seropositivity was greater for Healive® than for H2 and Havrix® at 12 months (p-values < 0.001) and 24 months (p-values < 0.0001). Average GMCs for the H2, Healive®, Havrix®, and control groups, in mIU/ml, were 29.7, 81.0, 36.4, and 2.9, respectively at 12 months, and 30.9, 112.2, 44.3, and 2.9, respectively, at 24 months. GMCs were greater for Healive® than for H2 and Havrix® at 12 months (p-values < 0.0001 and < 0.001, respectively) and 24 months (p-values < 0.001). No statistically significant differences inABSTRACT: Objective : Compare immune persistence from one dose of each of 3 different hepatitis A vaccines when given to school-age children: a domestic, live attenuated hepatitis A vaccine (H2 vaccine); a domestic inactivated hepatitis A vaccine (Healive®); and an imported, inactivated hepatitis A vaccine (Havrix®), .Methods : School-age children were randomized into 1 of 4 groups to receive a single dose of a vaccine: H2 vaccine, Healive®, Havrix®, or hepatitis B vaccine [control]. Serum samples were collected 12 and 24 months after vaccination for measurement of anti-HAV IgG using microparticle enzyme immunoassay. Seropositivity was defined as ≥ 20 mUI/ml. We compared groups on seropositivity and geometric mean concentration (GMC).Results : Seropositive rates for the H2, Healive®, Havrix®, and control groups were 64%, 94.4%, 73%, and 1.0%, respectively, 12-months post-vaccination; and 63%, 95.6%, 72%, and 1.0%, respectively 24-months post-vaccination. Seropositivity was greater for Healive® than for H2 and Havrix® at 12 months (p-values < 0.001) and 24 months (p-values < 0.0001). Average GMCs for the H2, Healive®, Havrix®, and control groups, in mIU/ml, were 29.7, 81.0, 36.4, and 2.9, respectively at 12 months, and 30.9, 112.2, 44.3, and 2.9, respectively, at 24 months. GMCs were greater for Healive® than for H2 and Havrix® at 12 months (p-values < 0.0001 and < 0.001, respectively) and 24 months (p-values < 0.001). No statistically significant differences in seropositivity or GMC were found within groups between 12 and 24 months.Conclusion : Immunity persisted 24 months after a single dose of inactivated hepatitis A vaccine and live attenuated hepatitis A vaccine. … (more)
- Is Part Of:
- Human vaccines & immunotherapeutics. Volume 12:Issue 9(2016)
- Journal:
- Human vaccines & immunotherapeutics
- Issue:
- Volume 12:Issue 9(2016)
- Issue Display:
- Volume 12, Issue 9 (2016)
- Year:
- 2016
- Volume:
- 12
- Issue:
- 9
- Issue Sort Value:
- 2016-0012-0009-0000
- Page Start:
- 2322
- Page End:
- 2326
- Publication Date:
- 2016-09-01
- Subjects:
- Hepatitis A vaccine -- immune persistence -- single dose
Vaccines -- Periodicals
615.372 - Journal URLs:
- http://www.tandfonline.com/toc/khvi20/current ↗
http://www.tandfonline.com/ ↗ - DOI:
- 10.1080/21645515.2015.1134069 ↗
- Languages:
- English
- ISSNs:
- 2164-5515
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4336.468655
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 2090.xml